Fluorometholone acetate. A new ophthalmic derivative of fluorometholone.
Hourly topical administration of 0.1% fluorometholone acetate ophthalmic suspension produced, on the average, a 47% reduction in the polymorphonuclear leukocytes invading the cornea during an experimentally induced inflammatory keratitis. This is a significantly greater anti-inflammatory effect than we have previously reported for the alcohol derivative of fluorometholone and is not significantly different from the therapeutic effect of 1.0% prednisolone acetate ophthalmic suspension, the most effective corneal anti-inflammatory agent that we have studied to date. Fluorometholone acetate (0.1%) formulated as a high-viscosity carbomer gel and applied at three-hour intervals reduced invading leukocytes in the cornea an average of 48%, an effect not significantly different from hourly administration of the suspension.
D000085:Acetates / Q000627:therapeutic use; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004334:Drug Administration Schedule; D005260:Female; D005469:Fluorometholone / Q000494:pharmacology / Q000627:therapeutic use*; D007634:Keratitis / Q000188:drug therapy*; D007962:Leukocytes / Q000187:drug effects; D008297:Male; D011239:Prednisolone / Q000031:analogs & derivatives / Q000627:therapeutic use; D011817:Rabbits
D000085:Acetates; D000893:Anti-Inflammatory Agents; C009935:prednisolone acetate; D011239:Prednisolone; D005469:Fluorometholone